About
Efranat Pharma is developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. The technology is based on the concept of engaging the bodys own immune system and harnessing it against cancer. Efranat has succeeded in engineering a natural vitamin D binding protein into a potent immune modulator to fight cancer and chronic viral diseases. The companys primary product, EF-022, is an immunomodulator that activates macrophages, a group of white blood cells that play a key role in the immune systems defense against cancer. The product is manufactured and processed under GMP in a procedure that mimics the natural process in the body. A test involving 14 dogs with cancer that were treated with EF-022 showed promising results. Efranat is currently conducting a phase 1 clinical trial in human cancer patients with advanced solid tumors at the Sheba Medical Center.
Funding history · 1 round · $4.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of Efranat Pharma's therapeutic development?
- Efranat Pharma is developing an anticancer immunotherapy treatment that utilizes a natural plasma protein molecule to engage the body's immune system against cancer.
- What is the status of Efranat Pharma as of November 2018?
- Efranat Pharma became inactive in November 2018, ceasing operations.
- What is the key product developed by Efranat Pharma?
- Efranat Pharma's primary product is EF-022, an immunomodulator engineered from a natural vitamin D binding protein. It is designed to activate macrophages to fight cancer and chronic viral diseases.
- What were the results of EF-022 testing in animals?
- A test involving 14 dogs with cancer treated with EF-022 showed promising results.
- What clinical trial stage was Efranat Pharma conducting for EF-022?
- Efranat Pharma was conducting a phase 1 clinical trial for EF-022 in human cancer patients with advanced solid tumors at the Sheba Medical Center.
- When was Efranat Pharma founded?
- Efranat Pharma was founded in December 2009.
- What was the total amount raised by Efranat Pharma and when was its last funding round?
- Efranat Pharma raised a total of $4,500,000 in a Seed round in November 2014.
- Who were some of the investors in Efranat Pharma's Seed round?
- Key investors in Efranat Pharma's Seed round in November 2014 included Yuval Yanai and Isaac-Friedman.
- How many employees did Efranat Pharma have?
- Efranat Pharma had approximately 10 employees.